LEO Pharma Expands Delgocitinib Data with Positive Real-World and…

Event summary

LEO Pharma presented six new data sets on delgocitinib cream at EADV 2026, including real-world adult outcomes and new adolescent data for Chronic Hand Eczema (CHE).
Interim results from the REACHED study showed 28.6% of adult patients achieved clear or almost clear skin after 8 weeks of treatment.
DELTA TEEN trial data indicated significant improvements in itch, pain, and quality of life for adolescents with CHE.
Delgocitinib cream is approved in multiple regions, including the EU, UK, and US, for moderate to severe CHE in adults.

The big picture

LEO Pharma's latest data reinforces delgocitinib's role in addressing the unmet needs of CHE patients, particularly in adolescents where treatment options are limited. The real-world evidence from the REACHED study strengthens its position in a competitive dermatology market, where patient-reported outcomes and quality-of-life improvements are increasingly critical for regulatory and commercial success. With approvals already in key markets, the focus now shifts to expanding its reach and demonstrating sustained efficacy in broader patient populations.

What we're watching

Regulatory Expansion: Whether LEO Pharma can secure additional approvals for delgocitinib in adolescent CHE, expanding its market potential.
Market Penetration: The pace at which delgocitinib gains adoption in real-world clinical practice, particularly in regions with high CHE prevalence.
Competitive Positioning: How LEO Pharma differentiates delgocitinib from existing treatments, leveraging its non-steroidal mechanism and quality-of-life data.